|
ES2527760T3
(es)
|
1998-07-23 |
2015-01-29 |
Yeda Research And Development Co., Ltd. |
Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
|
|
WO2000005250A1
(en)
|
1998-07-23 |
2000-02-03 |
Yeda Research And Development Co., Ltd |
Treatment of autoimmune conditions with copolymer 1 and related copolymers and peptides
|
|
JP2003521448A
(ja)
*
|
1998-07-23 |
2003-07-15 |
ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ |
合成ペプチドおよび自己免疫疾患治療のための使用方法
|
|
US6800287B2
(en)
|
1998-09-25 |
2004-10-05 |
Yeda Research And Development Co., Ltd. |
Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
|
|
WO2000074676A1
(en)
*
|
1999-06-04 |
2000-12-14 |
Vereniging Voor Christelijk Wetenschappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
US6872739B1
(en)
*
|
1999-06-04 |
2005-03-29 |
Vereniging Voor Christelijk Wetenshappelikjk Onderwijs |
Use of riluzole for the treatment of multiple sclerosis
|
|
MXPA02008023A
(es)
*
|
2000-02-18 |
2005-06-30 |
Yeda Res & Dev |
Formulaciones de copolimero 1 para dosificacion oral, nasal y pulmonar.
|
|
US7022663B2
(en)
|
2000-02-18 |
2006-04-04 |
Yeda Research And Development Co., Ltd. |
Oral, nasal and pulmonary dosage formulations of copolymer 1
|
|
US20020077278A1
(en)
|
2000-06-05 |
2002-06-20 |
Yong V. Wee |
Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
AU7528001A
(en)
*
|
2000-06-05 |
2001-12-17 |
Teva Pharma |
The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
|
|
WO2002076503A1
(en)
|
2000-06-20 |
2002-10-03 |
Mayo Foundation For Medical Education And Research |
Treatment of central nervous system diseases by antibodies against glatiramer acetate
|
|
US7429374B2
(en)
|
2001-12-04 |
2008-09-30 |
Teva Pharmaceutical Industries, Ltd. |
Process for the measurement of the potency of glatiramer acetate
|
|
PL215263B1
(pl)
|
2002-02-25 |
2013-11-29 |
Elan Pharm Inc |
Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
|
|
KR20050114212A
(ko)
*
|
2003-01-24 |
2005-12-05 |
엘란 파마슈티칼스, 인크. |
수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물
|
|
PL1797109T3
(pl)
|
2004-09-09 |
2016-11-30 |
|
Mieszaniny polipeptydów, kompozycje zawierające je i procesy ich wytwarzania oraz ich zastosowania
|
|
SI2949335T1
(sl)
|
2009-08-20 |
2017-05-31 |
Yeda Research & Development Company, Ltd. |
Nizkofrekventna terapija z glatiramer acetatom
|
|
USRE49251E1
(en)
|
2010-01-04 |
2022-10-18 |
Mapi Pharma Ltd. |
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
|
|
US8759302B2
(en)
|
2010-03-16 |
2014-06-24 |
Teva Pharmaceutical Industries, Ltd. |
Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
|
|
ES2602977T3
(es)
|
2010-10-11 |
2017-02-23 |
Teva Pharmaceutical Industries Ltd. |
Biomarcadores de citocinas como biomarcadores predictivos de la respuesta clínica para acetato de glatirámero
|
|
TW201326399A
(zh)
|
2011-10-10 |
2013-07-01 |
Teva Pharma |
用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
|
|
EP2906719A4
(en)
|
2012-10-10 |
2016-11-09 |
Teva Pharma |
PREDICTIVE BIOMARKER FOR CLINICAL REACTION FOR GLATIRAMERACETATE
|
|
UY35790A
(es)
|
2013-10-21 |
2015-05-29 |
Teva Pharma |
Marcadores genéticos que predicen la respuesta al acetato de glatiramer
|
|
CN105884866B
(zh)
*
|
2015-01-26 |
2021-04-20 |
漳州未名博欣生物医药有限公司 |
格拉替雷的化学合成方法
|
|
US9155775B1
(en)
|
2015-01-28 |
2015-10-13 |
Teva Pharmaceutical Industries, Ltd. |
Process for manufacturing glatiramer acetate product
|
|
CN112649538B
(zh)
*
|
2015-04-28 |
2024-03-29 |
深圳翰宇药业股份有限公司 |
多肽混合物高效液相色谱分析方法
|
|
US12097292B2
(en)
|
2016-08-28 |
2024-09-24 |
Mapi Pharma Ltd. |
Process for preparing microparticles containing glatiramer acetate
|
|
HRP20250396T1
(hr)
|
2016-08-31 |
2025-05-23 |
Mapi Pharma Ltd. |
Depo sustavi koji sadrže glatiramer acetat
|
|
AU2018242998B2
(en)
|
2017-03-26 |
2023-11-02 |
Mapi Pharma Ltd. |
Glatiramer depot systems for treating progressive forms of multiple sclerosis
|
|
WO2019002228A1
(en)
|
2017-06-26 |
2019-01-03 |
Institut Pasteur |
TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
|